# TALOS THERAPEUTICS, INC.: Optimization of brain-permeable CK2 inhibitors to inhibit neuroinflammation and metabolic dysfunction in Alzheimer's disease

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | TALOS THERAPEUTICS, INC. |
| Location | SAN DIEGO, CA |
| Project | Optimization of brain-permeable CK2 inhibitors to inhibit neuroinflammation and metabolic dysfunction in Alzheimer's disease |
| Project number | 1R43AG099398-01 |
| Mechanism | R43 |
| Institute | National Institute on Aging |
| Award | $497,554 |
| Awarded | 2026-09-17 |
| Project period | 2026-09-23 to 2027-09-22 |
| UEI | M697RXNSKH58 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11312459). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.